<sentence id="0">Acetylation genotype and phenotype in patients with systemic lupus erythematosus .</sentence>
<sentence id="1">Systemic lupus erythematosus ( SLE ) is a chronic autoimmune disease affecting various tissues and organs .</sentence>
<sentence id="2">In the studies on SLE etiopathogenesis , a <scope type="spec" id="0"> <cue type="spec" id="0">potential</cue> role of genetically determined impairment of xenobiotic metabolism</scope> has been emphasized .</sentence>
<sentence id="3">N-acetyltransferase 2 enzyme ( NAT2 ) exhibits gene polymorphism and the acetylation rate with NAT2 involvement varies from person to person .</sentence>
<sentence id="4">The study on acetylation phenotype was carried out using isonicotinic acid hydrazide ( isoniazid ) as a model drug , while NAT2 alleles were determined by the polymerase chain reaction-restriction fragment length polymorphism ( PCR-RFLP ) assays .</sentence>
<sentence id="5">Among patients with SLE , NAT2*4/NAT2*6 and NAT2*5/NAT2*5 genotypes occurred most frequently , while NAT2*4/NAT2*6 and NAT2*5/NAT2*6 prevailed in the control group .</sentence>
<sentence id="6">The concordance of 96.8 % was achieved between acetylation phenotype and NAT2 genotype in the group of SLE patients studied .</sentence>
<sentence id="7">Conclusion : Acetylation polymorphism appears <scope type="neg" id="1"><cue type="neg" id="1">not</cue> to be an important risk factor in SLE</scope> .</sentence>